Guido Baietto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guido Baietto has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Chandra Bortolotto
Radiology Institute, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy, Italy
2 shared publications - Francesco Agustoni
Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy
2 shared publications - Giulia Maria Stella
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy
2 shared publications - Jessica Saddi
Unit of Radiation Therapy, Department of Oncology, Clinical-Surgical, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
2 shared publications Alessandro Berni
Thoracic Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
1 shared publication- Angelo Guido Corsico
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy
1 shared publication
Latest Publications
- 10 November 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 1200
Integration of different robotic platforms in a thoracic surgery program: perioperative outcomes and learning curves from a prospective clinical implementation study
- 10 November 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 1200
Integration of different robotic platforms in a thoracic surgery program: perioperative outcomes and learning curves from a prospective clinical implementation study
- Open Access
- 24 April 2025
- Published by MDPI AG in Preprints.org
Rechallenge with Chemotherapy Versus Best Supportive Care for the Treatment of Malignant Pleural Mesothelioma in Advanced Lines: A Single-Institution Comparative Case Analysis
Background: Malignant mesothelioma is a rare and aggressive tumor, primarily affecting the pleural lining of the lungs. Our study aims to assess the survival benefit of chemotherapy rechallenge, in patients with no further chemotherapy options, compared to best supportive care, and to identify predictive factors for response to this strategy.Materials and Methods: We retrospectively analyzed data from 163 patients affected by MPM since November 2018. Of these, 41 patients, with advanced stage of disease and previously treated, were evaluated for chemotherapy rechallenge with platinum-pemetrexed regimen or were candidate only to palliative and supportive care. These two populations were compared in terms of overall survival outcomes.Results: When comparing median survival times, a significant difference was observed between the two study groups, with patients treated with platinum-pemetrexed rechallenge reaching approximately 20 months of median survival, while those receiving palliative care only 3 months. Survival percentages at different time intervals show that five months after the decision to undergo rechallenge or begin palliative care, the survival rate for the latter group was 27.27%, which is significantly lower than the 81.57% survival rate in the rechallenge one. Cox regression analysis confirmed rechallenge as a significant predictor of improved survival (HR 0.12, p < 0.001). Conclusion: Our findings suggest a potential survival benefit associated with the use of platinum-pemetrexed rechallenge in selected patients with advanced-stage, pretreated MPM. Further studies with larger cohorts are needed to validate these results.
- 24 April 2025
- Published by MDPI AG in Preprints.org
Open AccessRechallenge with Chemotherapy Versus Best Supportive Care for the Treatment of Malignant Pleural Mesothelioma in Advanced Lines: A Single-Institution Comparative Case Analysis
Background: Malignant mesothelioma is a rare and aggressive tumor, primarily affecting the pleural lining of the lungs. Our study aims to assess the survival benefit of chemotherapy rechallenge, in patients with no further chemotherapy options, compared to best supportive care, and to identify predictive factors for response to this strategy.Materials and Methods: We retrospectively analyzed data from 163 patients affected by MPM since November 2018. Of these, 41 patients, with advanced stage of disease and previously treated, were evaluated for chemotherapy rechallenge with platinum-pemetrexed regimen or were candidate only to palliative and supportive care. These two populations were compared in terms of overall survival outcomes.Results: When comparing median survival times, a significant difference was observed between the two study groups, with patients treated with platinum-pemetrexed rechallenge reaching approximately 20 months of median survival, while those receiving palliative care only 3 months. Survival percentages at different time intervals show that five months after the decision to undergo rechallenge or begin palliative care, the survival rate for the latter group was 27.27%, which is significantly lower than the 81.57% survival rate in the rechallenge one. Cox regression analysis confirmed rechallenge as a significant predictor of improved survival (HR 0.12, p < 0.001). Conclusion: Our findings suggest a potential survival benefit associated with the use of platinum-pemetrexed rechallenge in selected patients with advanced-stage, pretreated MPM. Further studies with larger cohorts are needed to validate these results.
- Open Access
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets
Background: Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6–18 months. Objectives: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy. Methods: This review examines advancements in understanding PM’s genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets. Results: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.
Open AccessMalignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets
Background: Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6–18 months. Objectives: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy. Methods: This review examines advancements in understanding PM’s genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets. Results: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.